Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis

Current Atherosclerosis Reports

Volumn 4, Issue 5, 2002, Pages 363-372

  Lonn, Eva ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Angiotensin Receptor Blocker; Losartan; Ramipril; Telmisartan; Valsartan

Indexed keywords

ANGIOTENSIN RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTERIOSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HOSPITALIZATION; HUMAN; MALE; MORTALITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARTERIOSCLEROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0345147666     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-002-0074-7     Document Type: Article

References (51)

1. Dzau VJ: Tissue angiotensin and pathobiology of vascular disease—a unifying hypothesis. Hypertension 2001, 37:1047–1052.
2. Jackson EK: Renin and angiotensin. In Goodman & Gilman’s The Pharmacological Basis of Therapeutics. Edited by Hardman JG, Limbird LE, Gilman AG. USA: McGraw-Hill; 2001.
3. Dzau VJ, Bernstein K, Celermeier D, et al.: The relevance of tissue angiotensin-converting enzyme; manifestations in mechanistic and endpoint data. Am J Cardiol 2001, 88(suppl):1L-20L. DOI: 10.1016/S0002-9149(01)01878-1
4. Blume A, Kaschina E, Unger T: Angiotensin II type 2 receptors: signalling and pathophysiological role. Curr Opin Nephrol Hypertens 2001, 10:234–246.
5. Tallant EA, Ferrario CM: State-of-the-art lecture. Antiproliferative actions of angiotensin-(1–7) in vascular smooth muscle. Hypertension 1999, 34:950–957.
6. Diet F, Pratt RE, Berry GJ, et al.: Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996, 94:2756–2767.
7. Cobanian AV, Haudenschild CC, Nickerson C, et al.: Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990, 15:327–331.
8. Aberg G, Ferrer P: Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990, 15:S65-S72. DOI: 10.1097/00005344-199015004-00022
9. Rolland PH, Carpiot P, Friggi A, et al.: Effects of angiotensin-converting enzyme inhibition with perindopril on hemodynamics, arterial structure and wall rheology in the hindquarters of atherosclerotic mini-pigs. Am J Cardiol 1993, 71:22E-27E. DOI: 10.1016/0002-9149(93)90948-C
10. Powell JS, Clozel JP, Muller RK, et al.: Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989, 245:186–188. DOI: 10.1126/science.2526370
11. Hoshida S, Nishida M, Yamashita N, et al.: Vascular angiotensin-converting enzyme activity in cholesterol-fed rabbits: effects of enalapril. Atherosclerosis 1997, 130:53–59. DOI: 10.1016/S0021-9150(96)06045-5
12. Mancini GB, Henry GC, Macaya C, et al.: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996, 94:258–265.
13. Schlaifer JD, Wargovich TJ, O’Neill B, et al.: Effects of quinapril on coronary blood flow in coronary artery disease patients with endothelial dysfunction. TREND Investigators. Trial on Reversing Endothelial Dysfunction. Am J Cardiol 1997, 80:1594–1597. DOI: 10.1016/S0002-9149(97)00750-9
14. Anderson TJ, Elstein E, Haber H, et al.: Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000, 35:60–66. DOI: 10.1016/S0735-1097(99)00537-9
15. Wilmink H, Banga JD, Hijmering M, et al.: Effect of angiotensin-converting enzyme inhibition and angiotensin II type I receptor antagonism on postprandial endothelial function. J Am Coll Cardiol 1999, 34:140–145. DOI: 10.1016/S0735-1097(99)00154-0
16. Vaughan DE, Rouleau JL, Ridker PM: Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation 1997, 96:442–447.
17. Wright RA, Flapan AD, Alberti KG: Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994, 24:67–73. DOI: 10.1016/0735-1097(94)90543-6
18. Brown NJ, Agirbasli MA, Williams GH, et al.: Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998, 32:965–971.
19. Brown NJ, Abbas A, Byren D, et al.: Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women. Circulation 2002, 105:304–309. DOI: 10.1161/hc0302.102570
20. Brown NJ, Agirbasli M, Vaughan DE: Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 1999, 34:285–290.
21. Cashin-Hemphill L, Holmvang G, Chan RC, et al.: Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. Quinapril Ischemic Event Trial. Am J Cardiol 1999, 83:43–47. DOI: 10.1016/S0002-9149(98)00780-2
22. Teo KK, Burton JR, Buller CE, et al.: Long term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000, 102:1748–54.
23. MacMahon S, Sharpe N, Gamble G, et al.: Randomized, placebo-controlled trial of the angiotensin converting enzyme inhibitor, ramipril, in patients with coronary or occlusive arterial disease. J Am Coll Cardiol 2000, 36:438–443. DOI: 10.1016/S0735-1097(00)00736-1
24. Lonn E, Yusuf S, Dzavik V, et al., for the SECURE Investigators: Effects of ramipril and of vitamin E on atherosclerosis: results of the prospective randomized Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation 2001, 103:919–925.
25. Hosomi N, Mizushige K, Ohyama H, et al.: Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stoke 2001, 32:1539–1545.
26. Yusuf S, Pepine CJ, Garces C, et al.: Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992, 340:1173–1178. DOI: 10.1016/0140-6736(92)92889-N
27. Rutherford JD, Pfeffer MA, Moye LA, et al.: Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation 1994, 90:1731–1738.
28. Kober L, Torp-Pedersen C, Carlsen JE, et al., for the Trandolapril Cardiac Evaluation (TRACE) Study Group: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992, 333:1670–1676. DOI: 10.1056/NEJM199512213332503
29. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993, 342:821–828.
30. Flather MC, Yusuf S, Køber L, et al.: Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000, 355:1575–1581. DOI: 10.1016/S0140-6736(00)02212-1
31. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000, 342:145–153. DOI: 10.1056/NEJM200001203420301
32. Pitt B, O’Neill B, Feldman R, et al.: The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001, 87:1058–1063. DOI: 10.1016/S0002-9149(01)01461-8
33. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033–1041. DOI: 10.1016/S0140-6736(01)06178-5
34. Pfeffer MA, Domanski M, Verter J, et al.: The continuation of the Prevention of Events With Angiotensin Converting Enzyme Inhibition (PEACE) Trial. Am Heart J 2001, 142:375–377. DOI: 10.1067/mhj.2001.117603
35. Pepine CJ: Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function. J Am Coll Cardiol 1996, 27:1048–1052. DOI: 10.1016/0735-1097(95)00605-2
36. Sun YP, Zhu BQ, Browne AE, et al.: Comparative effects of ACE inhibitors and an angiotensin receptor blocker on atherosclerosis and vascular function. J Cardiovasc Pharmacol Ther 2001, 6:175–181. DOI: 10.1177/107424840100600209
37. Strawn WB, Chappell MC, Dean RH, et al.: Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000, 101:1496–1497.
38. Ferrario CM: Use of angiotensin II receptor blockers in animal models of atherosclerosis. Am J Hypertens 2002, 15:9S-13S. DOI: 10.1016/S0895-7061(01)02274-9
39. Schjiffrin EL, Bae Park J, Intengan HD, et al.: Correction of arterial structure and endothelial dysfunction in human essential hypertension in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000, 101:1653–1659.
40. Hornig B, Landmesser U, Kohler C, et al.: Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001, 103:799–805.
41. Dahlöf B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995–1003. DOI: 10.1016/S0140-6736(02)08089-3
42. Lindholm LH, Ibsen H, Dahlöf B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004–1010. DOI: 10.1016/S0140-6736(02)08090-X
43. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860. DOI: 10.1056/NEJMoa011303
44. Brenner BM, Cooper ME, de Zeew D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–9. DOI: 10.1056/NEJMoa011161
45. Parving H, Lehnert H, Bröchner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870–878. DOI: 10.1056/NEJMoa011489
46. Pitt B, Segal R, Martinez FA, et al., on behalf of the ELITE Study Investigators: Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997, 349:747–752. DOI: 10.1016/S0140-6736(97)01187-2
47. Pitt B, Poole-Wilson PA, Segal R, et al., on behalf of the ELITE Study II Investigators: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355:1582–1587. DOI: 10.1016/S0140-6736(00)02213-3
48. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators: A randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675. DOI: 10.1056/NEJMoa010713
49. McKelvie RS, Yusuf S, Pericak D, et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 1999, 100:1056–1064.
50. Pfeffer M: Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers. Am Heart J 2000, 139:S23-S28. DOI: 10.1067/mhj.2000.102904
51. Yusuf S: From the HOPE to the ONTARGET and the TRANSCEND Studies: challenges in improving prognosis. Am J Cardiol 2002, 89(suppl):18A-26A. DOI: 10.1016/S0002-9149(01)02323-2